Today, Regeneron announced its successful acquisition of Decibel Therapeutics, strengthening their gene therapy programs and commitment to the hearing loss community. Read the news: https://bit.ly/3tbt9Qg To stay up to date on our team and progress, please follow Regeneron.
About us
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of building a world of connection for people with hearing and balance disorders. Guidelines: https://bit.ly/3IzmNvU
- Website
-
http://decibeltx.com
External link for Decibel Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Public Company
Locations
-
Primary
Get directions
1325 Boylston Street
Suite 500
Boston, MA 02215, US
Employees at Decibel Therapeutics
-
Seth Koehler
Director of Preclinical Development and Translation
-
Pete Weber
Chief Medical Officer. VC-Backed Biotech Business Builder and Senior Executive
-
Bridget Cleff
Vice President, Head of New Product Planning at Decibel Therapeutics
-
Jeffrey Schulz
Vice President, Finance | Controller | CPA
Updates
-
We are pleased to announce that our article "The natural history, clinical outcomes, and genotype–phenotype relationship of otoferlin-related hearing loss: a systematic, quantitative literature review" has been published online in Human Genetics. You can access the paper by using the following SharedIt link: https://rdcu.be/dlBPx
The natural history, clinical outcomes, and genotype–phenotype relationship of otoferlin-related hearing loss: a systematic, quantitative literature review - Human Genetics
link.springer.com
-
Today Decibel reported second quarter 2023 financial results and corporate updates. Read more: https://bit.ly/3Owk8Z1
-
-
Today we announced that we’ve entered into a definitive agreement with Regeneron to acquire Decibel and our pipeline of programs for hearing loss and balance disorders. Read important info: https://bit.ly/3KveZiw
-
-
While newborn hearing screening programs can identify irregularities in hearing, genetic testing can help pinpoint the specific molecular cause and inform clinical care for a child diagnosed with hearing loss. Learn more on our website: https://bit.ly/43Q0X21
Genetic Testing - Decibel Therapeutics
https://www.decibeltx.com